Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum

Source :: PR Newswire. April 27, 2023
Publication Year :: 2023
Abstract: Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1 2023 increased 10%, driven by volume growth [...]

Subjects :: Boehringer Ingelheim GmbH -- Company sales and earnings
Eli Lilly and Co. -- Company sales and earnings
Pipe lines
Atopic dermatitis
Viral antibodies
Antibodies
Pharmaceutical industry -- Company sales and earnings
Company earnings/profit
Business
News, opinion and commentary
Jardiance (Medication)
Trulicity (Medication)
Verzenio (Medication)
Mounjaro (Medication)

Tools